Necitumumab for patients with non-squamous NSCLC: uninspiring results
Mené sur 633 patients atteints d'un cancer non épidermoïde du poumon non à petites cellules de stade IV, cet essai multicentrique international évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de necitumumab à un traitement de première ligne combinant pemetrexed et cisplatine
In The Lancet Oncology, Luis Paz-Ares and colleagues present the results of the INSPIRE study, a randomised, controlled phase 3 trial comparing cisplatin plus pemetrexed with and without necitumumab, a second-generation anti-EGFR monoclonal antibody, in 633 previously untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The addition of necitumumab to cisplatin plus pemetrexed did not improve overall survival compared with cisplatin plus pemetrexed alone (median overall survival 11·3 months [95% CI 9·5–13·4] vs 11·5 months [10·1–13·1]; hazard ratio 1·01 [95% CI 0·84–1·21]; p=0·96]).
The Lancet Oncology , commentaire, 2014